Torvutatug Samrotecan, With or Without Bevacizumab, as Ongoing Treatment for Relapsed Ovarian Cancer
Tests torvutatug samrotecan in adults whose platinum-sensitive ovarian cancer has returned.
Plain-language title generated from the registry record
Registry title: Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Key facts
- Where
- Beijing, Chengdu, Guangdong Province, Guangzhou, Hangzhou, Nanchang, Wuhan, and Zhengzhou, ChinaSee the 8 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women whose ovarian, fallopian tube or primary peritoneal cancer came back 6 or more months after platinum chemotherapy and who have already finished platinum chemotherapy without the disease getting worse.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- High-grade epithelial serous or endometrioid ovarian, fallopian tube or primary peritoneal cancer that has come back (relapsed) at least 6 months after the last platinum chemotherapy, confirmed by scans. The disease must not be getting worse after platinum chemotherapy.
- Earlier treatment
- 1 or 2 earlier lines of systemic anticancer treatment. 4-6 cycles of platinum chemotherapy in the current line. People assigned to bevacizumab need at least 3 cycles of bevacizumab with 3 cycles of platinum chemotherapy first. Those with a BRCA1/2 mutation must have had a PARP inhibitor, unless they could not take it.
- Biomarker or test result
- An archival tumour sample (FFPE) must be provided. A documented BRCA 1/2 mutation is mentioned: those people must have had a PARP inhibitor before.
Main reasons for not taking part
- Non-epithelial tumours, borderline tumours, clear cell, mucinous, carcinosarcoma or low-grade epithelial tumours
- Past or current lung inflammation (ILD/pneumonitis) that needed steroids or oxygen
- Non-healing wound, active ulcer or bone fracture (if receiving bevacizumab)
- Active or ongoing bowel obstruction (if receiving bevacizumab)
- Earlier treatment targeting FRα, including MIRV, or any TOP1i antibody-drug conjugate
Read by machine on 9 November 2026.
Where in China
- BeijingBeijing, ChinaNot yet recruiting
- ChengduChengdu, ChinaNot yet recruiting
- Guangdong ProvinceGuangdong Province, ChinaNot yet recruiting
- GuangzhouGuangzhou, ChinaNot yet recruiting
- HangzhouHangzhou, ChinaNot yet recruiting
- NanchangNanchang, ChinaNot yet recruiting
- WuhanWuhan, ChinaNo longer taking part
- ZhengzhouZhengzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07816666EU 2026-526776-23-00
- Record updated
- 16 October 2026
- Original description
The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)Read full original descriptionShow less
A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)
The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)
Inclusion: Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer; Provision of an archival FFPE tumour sample; Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy; Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment; Participants who received 4-6 cycles of PBC during the induction phase of their current line of treatment; Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation; Participants with non-progressive disease upon completion of PBC in their current line of treatment; Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance).
Exclusion: Participants with non-healing wound, active ulcer, or bone fracture (not applicable if not receiving bevacizumab); Participants with evidence of active or ongoing bowel obstruction (not applicable if not receiving bevacizumab); Participants with prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC); Participants with history of (non-infectious) ILD/pneumonitis that required steroids, or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening; Participants with tumours of non-epithelial origin, borderline tumours, clear cell OC, mucinous OC, carcinosarcoma, or low-grade epithelial tumours.